Effect of BRAF‑mediated PI3K/Akt/mTOR pathway on biological characteristics and chemosensitivity of NSCLC A549/DDP cells

Ren,Bingnan; Liu,Hongtao; Yang,Yupeng; Lian,Yufei

doi:10.3892/ol.2021.12845

Effect of BRAF‑mediated PI3K/Akt/mTOR pathway on biological characteristics and chemosensitivity of NSCLC A549/DDP cells

Authors:
- Bingnan Ren
- Hongtao Liu
- Yupeng Yang
- Yufei Lian
View Affiliations

Affiliations: Department of Pharmacy, Hebei General Hospital, Shijiazhuang, Hebei 050053, P.R. China
Published online on: June 3, 2021 https://doi.org/10.3892/ol.2021.12845
Article Number: 584
Copyright: © Ren et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to explore the biological characteristics of non‑small cell lung cancer (NSCLC) cells and the mechanism of chemosensitivity through the role of the PI3K/Akt/mTOR signaling pathway mediated by BRAF gene silencing. Following cell transfection and grouping, an MTT assay detected the activity of NSCLC cells, a scratch wound test assessed the migration ability, flow cytometry using PI staining detected the cell cycle phase, TUNEL and flow cytometry through Annexin V‑PI staining assessed the apoptosis, and colony formation was used to detect the sensitivity of lung cancer cells to cisplatin chemotherapy. Furthermore, the relative expression levels of BRAF, PTEN, PI3K, mTOR mRNA were assessed by RT‑qPCR, and the protein expression levels of BRAF, PTEN, PI3K, phosphorylated (p)‑PI3K, Akt, p‑Akt, mTOR, p‑mTOR, cisplatin resistance‑related enzymes ERCC1 and BRCA1, apoptotic proteins Bax and Bcl‑2 were assessed by western blotting. Compared with the control group and NC group, there were differences in decreased BRAF mRNA expression levels in the small interfering (si)BRAF group and siBRAF + IGF‑1 group (both P<0.05). In addition, compared with the control group, the siBRAF, NVP‑BEZ235 and siBRAF + NVP‑BEZ235 groups had significant decreased cell viability at 2‑6 days, decreased migration ability, shortened proportion of S‑phase cells, increased proportion of G1/G0‑phase cells, increased apoptosis rate, decreased number of colony‑forming cells, decreased mRNA expression of PI3K, Akt and mTOR, increased PTEN mRNA expression, decreased protein expression levels of PI3K, p‑PI3K, Akt, p‑Akt, mTOR, p‑mTOR, ERCC1, BRCA1 and Bcl‑2, and increased protein expression levels of PTEN and Bax (all P<0.05); and more obvious trends were revealed in the siBRAF + NVP‑BEZ235 group (all P<0.05); whereas opposite results were detected in the siBRAF + IGF‑1 group when compared with the siBRAF group and NVP‑BEZ235 group (all P<0.05). Silencing of BRAF gene expression to inhibit the activation of the PI3K/Akt/mTOR signaling pathway exerted a synergistic effect decreasing cell viability, inhibiting the cell cycle and migration, increasing the apoptosis rate, decreasing the number of colony‑forming cells and increasing chemosensitivity of NSCLC. Activation of the PI3K/Akt/mTOR signaling pathway may reverse the role of silencing of BRAF gene expression, providing a potential approach for improving the chemosensitivity of NSCLC. The present study for the first time, to the best of our knowledge, clarified the possible mechanism of NSCLC cell biological characteristic changes and chemosensitivity from the perspective of BRAF gene silencing and PI3K/Akt/mTOR signaling pathway activation, providing a potential reference for suppressing tumor aggravation and improving the therapeutic outcomes of NSCLC at the genetic level.

View Figures

View References

1	Masel EK, Berghoff AS, Füreder LM, Heicappell P, Schlieter F, Widhalm G, Gatterbauer B, Dieckmann U, Birner P, Bartsch R, et al: Decreased body mass index is associated with impaired survival in lung cancer patients with brain metastases: A retrospective analysis of 624 patients. Eur J Cancer Care (Engl). 26:e127072017. View Article : Google Scholar : PubMed/NCBI
2	Sui T, Liu A and Jiao W: Difference of lung function retention after segmentectomy and lobectomy. Zhongguo Fei Ai Za Zhi. 22:178–182. 2019.PubMed/NCBI
3	Wang W, Zhang L, Liu L, Zheng Y, Zhang Y, Yang S, Shi R and Wang S: Chemosensitizing effect of shRNA-mediated ERCC1 silencing on a Xuanwei lung adenocarcinoma cell line and its clinical significance. Oncol Rep. 37:1989–1997. 2017. View Article : Google Scholar : PubMed/NCBI
4	Levy A, Faivre-Finn C, Hasan B, De Maio E, Berghoff AS, Girard N, Greillier L, Lantuéjoul S, O'Brien M, Reck M, et al: Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey. Eur J Cancer. 93:37–46. 2018. View Article : Google Scholar : PubMed/NCBI
5	Majem M, Juan O, Insa A, Reguart N, Trigo JM, Carcereny E, García-Campelo R, García Y, Guirado M and Provencio M: SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). Clin Transl Oncol. 21:3–17. 2019. View Article : Google Scholar : PubMed/NCBI
6	Cheng L, Gao E, Zhu F, Wang Y, Zhong J and An T: A case report on successful third challenge to the Pemetrexed-based regimen for advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 22:395–400. 2019.PubMed/NCBI
7	Zhang Y: Chemotherapy in advanced non-small cell lung cancer: Present and future. J Int Transl Med. 5:38–44. 2017.
8	Matsufuji H, Shiozaki E, Nakatake Y, Yoshida K, Kamada K and Matsuo T: A case of slowly progressive brain metastasis with minor bleeding after removal of and chemotherapy for non-small cell lung cancer. No Shinkei Geka. 45:339–344. 2017.PubMed/NCBI
9	Farré PL, Scalise GD, Duca RB, Dalton GN, Massillo C, Porretti J, Graña K, Gardner K, De Luca P and De Siervi A: CTBP1 and metabolic syndrome induce an mRNA and miRNA expression profile critical for breast cancer progression and metastasis. Oncotarget. 9:13848–13858. 2018. View Article : Google Scholar
10	Zhang L, Wang Y, Rashid MH, Liu M, Angara K, Mivechi NF, Maihle NJ, Arbab AS and Ko L: Malignant pericytes expressing GT198 give rise to tumor cells through angiogenesis. Oncotarget. 8:51591–51607. 2017. View Article : Google Scholar : PubMed/NCBI
11	Glentis A, Oertle P, Mariani P, Chikina A, El Marjou F, Attieh Y, Zaccarini F, Lae M, Loew D, Dingli F, et al: Cancer-associated fibroblasts induce metalloprotease-independent cancer cell invasion of the basement membrane. Nat Commun. 8:9242017. View Article : Google Scholar : PubMed/NCBI
12	Oudin MJ and Weaver VM: Physical and chemical gradients in the tumor microenvironment regulate tumor cell invasion, migration, and metastasis. Cold Spring Harb Symp Quant Biol. 81:189–205. 2016. View Article : Google Scholar : PubMed/NCBI
13	Shen Y, Su C, Shi Y, Liu X and Zhao L: Chitosan nanoparticles promoted cancer cell invasion and metastasis via the massive production of reactive oxygen species. J Biomater Tissue Eng. 7:484–490. 2017. View Article : Google Scholar
14	Li N, Gao WJ and Liu NS: LncRNA BCAR4 promotes proliferation, invasion and metastasis of non-small cell lung cancer cells by affecting epithelial-mesenchymal transition. Eur Rev Med Pharmacol Sci. 21:2075–2086. 2017.PubMed/NCBI
15	Shimizu T, Asakuma M, Tomioka A, Inoue Y, Hirokawa F, Hayashi M and Uchiyama K: Span-1 and CA19-9 as predictors of early recurrence and lymph node metastasis for patients with invasive pancreatic cancer after pancreatectomy. Am Surg. 84:109–113. 2018. View Article : Google Scholar : PubMed/NCBI
16	Zhu BP, Guo ZQ, Lin L and Liu Q: Serum BSP, PSADT, and Spondin-2 levels in prostate cancer and the diagnostic significance of their ROC curves in bone metastasis. Eur Rev Med Pharmacol Sci. 21:61–67. 2017.PubMed/NCBI
17	Feng HM, Zhao Y, Zhang JP, Zhang JH, Jiang P, Li B and Wang C: Expression and potential mechanism of metabolism-related genes and CRLS1 in non-small cell lung cancer. Oncol Lett. 15:2661–2668. 2018.PubMed/NCBI
18	Choi H, Ding CG, Lee SB, Durrans A, Ryu S, Elemento O, Wong S, Altorki NK and Mittal V: Abstract 1159: A novel HGF-MET paracrine signaling pathway promotes growth and resistance to chemotherapy in lung cancer. Cancer Res. 74:11592014.
19	Bahrami A, Hasanzadeh M, Hassanian SM, ShahidSales S, Ghayour-Mobarhan M, Ferns GA and Avan A: The potential value of the PI3K/Akt/mTOR signaling pathway for assessing prognosis in cervical cancer and as a target for therapy. J Cell Biochem. 118:4163–4169. 2017. View Article : Google Scholar : PubMed/NCBI
20	Pan JH, Wang HB, Du XF, Liu JY and Zhang DJ: Polydatin induces human cervical cancer cell apoptosis via PI3K/AKT/mTOR signaling pathway. Zhongguo Zhong Yao Za Zhi. 42:2345–2349. 2017.PubMed/NCBI
21	Du C, Zhang T, Xiao X, Shi Y, Duan H and Ren Y: Protease-Activated Receptor-2 promotes kidney tubular epithelial inflammation by inhibiting autophagy via the PI3K/Akt/mTOR signalling pathway. Biochem J. 474:2733–2747. 2017. View Article : Google Scholar : PubMed/NCBI
22	Tian B, Zhao Y, Liang T, Ye X, Li Z, Yan D, Fu Q and Li Y: Curcumin inhibits urothelial tumor development by suppressing IGF2 and IGF2-mediated PI3K/AKT/mTOR signaling pathway. J Drug Target. 25:626–636. 2017. View Article : Google Scholar : PubMed/NCBI
23	Liu M, Tang R and Jiang Y: Pantoprazole induces apoptosis of leukemic cells by inhibiting expression of P-Glycoprotein/Multidrug Resistance-Associated Protein-1 Through PI3K/AKT/mTOR Signaling. Indian J Hematol Blood Transfus. 33:500–508. 2017. View Article : Google Scholar : PubMed/NCBI
24	Dalal AA, Guerin A, Mutebi A and Culver KW: Economic analysis of BRAF gene mutation testing in real world practice using claims data: Costs of single gene versus panel tests in patients with lung cancer. J Med Econ. 21:649–655. 2018. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Toffart AC, Duruisseaux M, Brichon PY, Pirvu A, Villa J, Selek L, Guillem P, Dumas I, Ferrer L, Levra MG and Moro-Sibilot D: Operation and chemotherapy: Prognostic factors for lung cancer with one synchronous metastasis. Ann Thorac Surg. 105:957–965. 2018. View Article : Google Scholar : PubMed/NCBI
27	Wang X, Zhang W, Du W, Zhang X, Ren X and Cao S: Efficacy and survival analysis of apatinib in patients with advanced nonsquamous non-small cell lung cancer after failure of first-line treatment. Zhongguo Fei Ai Za Zhi. 20:761–768. 2017.PubMed/NCBI
28	Farnie G, Sotgia F and Lisanti MP: High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant. Oncotarget. 6:30472–30486. 2015. View Article : Google Scholar : PubMed/NCBI
29	Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J and Engelman JA: BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells Harboring the BRAF V600E Mutation. Ence Signaling. 3:ra842010.PubMed/NCBI
30	Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, et al: Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad, USA 109. 109:E2127–E2133. 2012. View Article : Google Scholar : PubMed/NCBI
31	Xiao W, Tang H, Wu M, Liao Y, Li K, Li L and Xu X: Ozone oil promotes wound healing by increasing the migration of fibroblasts via PI3K/Akt/mTOR signaling pathway. Biosci Rep. 37:BSR201706582017. View Article : Google Scholar : PubMed/NCBI
32	Okada K, Nogami A, Ishida S, Akiyama H, Chen C, Umezawa Y and Miura O: FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway. Oncotarget. 9:8870–8886. 2017. View Article : Google Scholar : PubMed/NCBI
33	Fu JH, Yang S, Nan CJ, Zhou CC, Lu DQ, Li S and Mu HQ: miR-182 affects renal cancer cell proliferation, apoptosis, and invasion by regulating PI3K/AKT/mTOR signaling pathway. Eur Rev Med Pharmacol Sci. 24:72022020.PubMed/NCBI
34	Guoyin Z, Hao P, Min L, Wei G, Zhe C and Changquan L: Antihepatocarcinoma effect of Portulaca oleracea L. in Mice by PI3K/Akt/mTOR and Nrf2/HO-1/NF-κB Pathway. Evid Based Complement Alternat Med. 2017:82313582017. View Article : Google Scholar : PubMed/NCBI
35	Kim GD: Myricetin inhibits angiogenesis by inducing apoptosis and suppressing PI3K/Akt/mTOR signaling in endothelial cells. J Cancer Prev. 22:219–227. 2017. View Article : Google Scholar : PubMed/NCBI
36	Chen J, Crawford R and Xiao Y: Vertical inhibition of the PI3K/Akt/mTOR pathway for the treatment of osteoarthritis. J Cell Biochem. 114:245–249. 2013. View Article : Google Scholar : PubMed/NCBI
37	Burris HA III: Overcoming acquired resistance to anticancer therapy: Focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol. 71:829–842. 2013. View Article : Google Scholar : PubMed/NCBI
38	Zhang HY, Zhang PN and Sun H: Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy. Eur J Obstet Gynecol Reprod Biol. 146:81–86. 2009. View Article : Google Scholar : PubMed/NCBI
39	Cheng H, Shcherba M, Pendurti G, Liang Y, Piperdi B and Perez-Soler R: Targeting the PI3K/AKT/mTOR pathway: Potential for lung cancer treatment. Lung Cancer Manag. 3:67–75. 2014. View Article : Google Scholar : PubMed/NCBI
40	Xu JL, Wang ZW, Hu LM, Yin ZQ, Huang MD, Hu ZB, Shen HB and Shu YQ: Genetic Variants in the PI3K/PTEN/AKT/mTOR pathway predict Platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population. Asian Pac J Cancer Prev. 13:2157–2162. 2012. View Article : Google Scholar : PubMed/NCBI
41	Zhang Q, Lai S, Hou X, Cao W, Zhang Y and Zhang Z: Protective effects of PI3K/Akt signal pathway induced cell autophagy in rat knee joint cartilage injury. Am J Transl Res. 10:762–770. 2018.PubMed/NCBI
42	Cheriyan VT, Alsaab H, Sekhar S, Venkatesh J, Mondal A, Vhora I, Sau S, Muthu M, Polin LA, Levi E, et al: A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers. Oncotarget. 9:29680–29697. 2018. View Article : Google Scholar : PubMed/NCBI
43	Oei AL, van Leeuwen CM, Ahire VR, Rodermond HM, Ten Cate R, Westermann AM, Stalpers LJA, Crezee J, Kok HP, Krawczyk PM, et al: Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient Tumour cells with hyperthermia. Oncotarget. 8:28116–28124. 2017. View Article : Google Scholar : PubMed/NCBI
44	An SH, Kang JH, Kim DH and Lee MS: Vitamin C increases the apoptosis via up-regulation p53 during cisplatin treatment in human colon cancer cells. BMB Rep. 44:211–216. 2011. View Article : Google Scholar : PubMed/NCBI
45	Heymann PGB, Henkenius KSE, Ziebart T, Braun A, Hirthammer K, Halling F, Neff A and Mandic R: Modulation of tumor cell metabolism by laser photochemotherapy with cisplatin or zoledronic acid in vitro. Anticancer Res. 38:1291–1301. 2018.PubMed/NCBI
46	Nolte E, Wach S, Silva IT, Lukat S, Ekici AB, Munkert J, Müller-Uri F, Kreis W, Oliveira Simões CM, Vera J, et al: A new semisynthetic cardenolide analog 3β-[2-(1-amantadine)-1-on-ethylamine]-digitoxigenin (AMANTADIG) affects G2/M cell cycle arrest and miRNA expression profiles and enhances proapoptotic survivin-2B expression in renal cell carcinoma cell lines. Oncotarget. 8:11676–11691. 2017. View Article : Google Scholar : PubMed/NCBI
47	Xu C, Sun G, Yuan G, Wang R and Sun X: Effects of Platycodin D on proliferation, apoptosis and PI3K/Akt Signal Pathway of Human Glioma U251 Cells. Molecules. 19:21411–21423. 2014. View Article : Google Scholar : PubMed/NCBI
48	Li H, Hu J, Wu S, Wang L, Cao X, Zhang X, Dai B, Cao M, Shao R, Zhang R, et al: Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget. 7:3548–3558. 2016. View Article : Google Scholar : PubMed/NCBI
49	Ma HP, Kong WX, Li XY, Li W, Zhang Y and Wu Y: miRNA-223 is an anticancer gene in human non-small cell lung cancer through the PI3K/AKT pathway by targeting EGFR. Oncol Rep. 41:1549–1559. 2019.PubMed/NCBI
50	Wang H, Yu Z, Huo S, Chen Z, Ou Z, Mai J, Ding S and Zhang J: Overexpression of ELF3 facilitates cell growth and metastasis through PI3K/Akt and ERK signaling pathways in non-small cell lung cancer. Int J Biochem Cell Biol. 94:98–106. 2018. View Article : Google Scholar : PubMed/NCBI